MARKET

HCM

HCM

HUTCHMED (China) Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.93
+1.39
+3.70%
After Hours: 38.93 0 0.00% 16:41 09/17 EDT
OPEN
38.09
PREV CLOSE
37.54
HIGH
39.00
LOW
37.84
VOLUME
228.90K
TURNOVER
--
52 WEEK HIGH
43.94
52 WEEK LOW
23.67
MARKET CAP
6.73B
P/E (TTM)
-432.0755
1D
5D
1M
3M
1Y
5Y
BRIEF-Hutchmed (China) Says NMPA Granted Breakthrough Therapy Designation To Amdizalisib
reuters.com · 4d ago
HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China
Benzinga · 4d ago
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administrati...
GlobeNewswire · 5d ago
Hutchmed's Lymphoma Drug Candidate Granted Breakthrough Therapy Designation in China
MT Newswires · 5d ago
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (C...
GlobeNewswire · 09/08 10:30
AstraZeneca, Hutchmed Start Late-Stage Study on Lung Cancer Combination Therapy Candidate
MT Newswires · 09/08 07:43
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMP...
GlobeNewswire · 09/07 08:30
BUZZ-HK-listed SciClone Pharma jumps on inclusion in Shenzhen-HK stock connect program
reuters.com · 09/06 07:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HCM. Analyze the recent business situations of HUTCHMED (China) Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HCM stock price target is 47.39 with a high estimate of 54.76 and a low estimate of 36.20.
EPS
Institutional Holdings
Institutions: 178
Institutional Holdings: 53.87M
% Owned: 31.16%
Shares Outstanding: 172.87M
TypeInstitutionsShares
Increased
57
4.31M
New
24
1.00M
Decreased
38
4.65M
Sold Out
12
748.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
Simon To
Chief Executive Officer/Executive Director/IR Contact Officer
Christian Hogg
Chief Financial Officer/Executive Director
Chig Fung Cheng
Executive Director
Weiguo Su
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
No Data
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers kinds of HUTCHMED (China) Ltd stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.